| Combined inhibition of CDK4/6 and PI3K/AKT/mTOR pathways induces a synergistic anti-tumor effect in malignant pleural mesothelioma cells MA Bonelli, G Digiacomo, C Fumarola, R Alfieri, F Quaini, A Falco, ... Neoplasia 19 (8), 637-648, 2017 | 109 | 2017 |
| Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility A Ravelli, G Roviello, D Cretella, A Cavazzoni, A Biondi, MR Cappelletti, ... Tumor Biology 39 (4), 1010428317695023, 2017 | 106 | 2017 |
| Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines S La Monica, D Cretella, M Bonelli, C Fumarola, A Cavazzoni, ... Journal of Experimental & Clinical Cancer Research 36, 1-12, 2017 | 92 | 2017 |
| The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells D Cretella, A Ravelli, C Fumarola, S La Monica, G Digiacomo, ... Journal of Experimental & Clinical Cancer Research 37, 1-12, 2018 | 91 | 2018 |
| Anti-proliferative effects of copper (II) complexes with hydroxyquinoline-thiosemicarbazone ligands D Rogolino, A Cavazzoni, A Gatti, M Tegoni, G Pelosi, V Verdolino, ... European journal of medicinal chemistry 128, 140-153, 2017 | 83 | 2017 |
| Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells D Cretella, C Fumarola, M Bonelli, R Alfieri, S La Monica, G Digiacomo, ... Scientific reports 9 (1), 13014, 2019 | 82 | 2019 |
| Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance D Cretella, F Saccani, F Quaini, C Frati, C Lagrasta, M Bonelli, C Caffarra, ... Molecular cancer 13, 1-12, 2014 | 80 | 2014 |
| PTEN alterations as a potential mechanism for tumor cell escape from PD-1/PD-L1 inhibition D Cretella, G Digiacomo, E Giovannetti, A Cavazzoni Cancers 11 (9), 1318, 2019 | 79 | 2019 |
| Effect of ABCG2/BCRP expression on efflux and uptake of gefitinib in NSCLC cell lines M Galetti, PG Petronini, C Fumarola, D Cretella, S La Monica, M Bonelli, ... PloS one 10 (11), e0141795, 2015 | 73 | 2015 |
| Combination of gefitinib and pemetrexed prevents the acquisition of TKI resistance in NSCLC cell lines carrying EGFR-activating mutation S La Monica, D Madeddu, M Tiseo, V Vivo, M Galetti, D Cretella, M Bonelli, ... Journal of Thoracic Oncology 11 (7), 1051-1063, 2016 | 71 | 2016 |
| CDK4/6 inhibitors in HER2-positive breast cancer SP Corona, A Ravelli, D Cretella, MR Cappelletti, L Zanotti, M Dester, ... Critical reviews in oncology/hematology 112, 208-214, 2017 | 59 | 2017 |
| Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC S La Monica, R Minari, D Cretella, L Flammini, C Fumarola, M Bonelli, ... Journal of Experimental & Clinical Cancer Research 38, 1-12, 2019 | 53 | 2019 |
| Expanding the arsenal of FGFR inhibitors: a novel chloroacetamide derivative as a new irreversible agent with anti-proliferative activity against FGFR1-amplified lung cancer … C Fumarola, N Bozza, R Castelli, F Ferlenghi, G Marseglia, A Lodola, ... Frontiers in Oncology 9, 179, 2019 | 50 | 2019 |
| Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines A Cavazzoni, RR Alfieri, D Cretella, F Saccani, L Ampollini, M Galetti, ... Molecular cancer 11, 1-14, 2012 | 50 | 2012 |
| Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification S La Monica, C Caffarra, F Saccani, E Galvani, M Galetti, C Fumarola, ... PloS one 8 (10), e78656, 2013 | 49 | 2013 |
| Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene … MA Bonelli, A Cavazzoni, F Saccani, RR Alfieri, F Quaini, S La Monica, ... Molecular cancer therapeutics 14 (8), 1916-1927, 2015 | 47 | 2015 |
| Drug-induced cellular death dynamics monitored by a highly sensitive organic electrochemical system A Romeo, G Tarabella, P D’Angelo, C Caffarra, D Cretella, R Alfieri, ... Biosensors and Bioelectronics 68, 791-797, 2015 | 41 | 2015 |
| Acquired BRAF G469A mutation as a resistance mechanism to first-line osimertinib treatment in NSCLC cell lines harboring an EGFR exon 19 deletion S La Monica, R Minari, D Cretella, M Bonelli, C Fumarola, A Cavazzoni, ... Targeted Oncology 14, 619-626, 2019 | 40 | 2019 |
| Efficacy of the CDK4/6 dual inhibitor abemaciclib in EGFR-mutated NSCLC cell lines with different resistance mechanisms to osimertinib S La Monica, C Fumarola, D Cretella, M Bonelli, R Minari, A Cavazzoni, ... Cancers 13 (1), 6, 2020 | 35 | 2020 |
| Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer A Cavazzoni, G Digiacomo, R Alfieri, S La Monica, C Fumarola, M Galetti, ... Cancers 12 (3), 666, 2020 | 35 | 2020 |
